Inspira Technologies Oxy B.H.N. Ltd. reports developments in Additively Manufactured Electronics, quantum connectivity and its medical technology portfolio. Company updates focus on AME system orders and deployments, QTREX-branded cryogenic interconnect work for superconducting quantum systems, customer activity with research, defense and technology organizations, and leadership or strategic-direction announcements.
The company's medical technology context includes respiratory support and blood monitoring platforms, including INSPIRA ART, INSPIRA ART100 and the HYLA Blood Sensor, while recent communications emphasize a dedicated medical business unit alongside the AME and quantum connectivity strategy.
QTREX Quantum (Nasdaq: QTEX) priced a $10 million private placement of 6,666,667 ordinary shares (or equivalents) with a new institutional investor. Closing is expected around June 1, 2026, with net proceeds earmarked for working capital, corporate purposes, commercialization of AME-based cryogenic interconnects, and R&D.
QTREX Quantum (Nasdaq:IINN) is in advanced talks with a top-five global quantum computing company on a potential strategic collaboration. Both sides are running a joint technical evaluation of QTREX’s AME-based cryogenic interconnects within the partner’s refrigerator architecture.
If a definitive agreement is signed, the partner could adopt QTREX’s platform as its foundational cryogenic interconnect technology, embedding QTREX as a critical supplier across its future quantum hardware roadmap and aligning QTREX’s revenue prospects with the partner’s global deployment growth.
Inspira Technologies (Nasdaq: IINN) will change its corporate name to QTREX Quantum and begin trading under the new Nasdaq ticker QTEX on May 20, 2026. Warrants will trade as QTEXW. No shareholder action is required.
The new name highlights a strategic focus on its Additively Manufactured Electronics (AME) platform for advanced manufacturing, high‑performance electronics and quantum connectivity, targeting quantum computing connectivity inside dilution cryostats.
Inspira Technologies (Nasdaq:IINN) announced a $580,000 purchase order from NYU Langone Hospital for its FDA-cleared ART100 extracorporeal blood circulation systems, following a multi-patient hospital evaluation of more than 30 cases.
The order will be fulfilled immediately and serves as a key reference within Inspira’s ongoing strategic process for ART100 and related assets.
Inspira Technologies (NASDAQ:IINN) outlined a three-track plan focused on an AME electronics platform, quantum computing connectivity and monetization of its medical business. The company acquired Nano Dimension’s AME platform, signed a joint development deal with Qarakal Quantum, and reported over $1 million in recent AME transactions.
Management is reducing the legacy medical burn rate and exploring sales of medical assets by Q3 2026 to generate non-dilutive capital. FDA-cleared ART100 has treated 40+ patients, and HYLA is being prepared for FDA submission. Shareholders approved a name change to QTREX Quantum.
Inspira (Nasdaq: IINN) secured a $596,000 purchase order for an Additively Manufactured Electronics (AME) system from a leading Irish technological research university on May 1, 2026.
The order includes a 40% non-refundable upfront payment already received, with the balance due on delivery. Inspira expects delivery in the coming weeks, training for research teams, and recurring revenue from proprietary consumables, wear parts, and annual service fees tied to system usage. The installation is intended as a reference site for further academic and commercial engagements across Europe.
Inspira (Nasdaq: IINN) signed a Joint Development Agreement with Qarakal Quantum to test Inspira’s QTREX additively manufactured electronics in superconducting, cryogenic environments. The multi‑phase program will supply 3D‑printed conductive and insulating structures for milli‑Kelvin testing, with metrics, scope, timelines, and resource commitments to be finalized.
The collaboration targets high‑density routing, integrated transitions, embedded shielding, rigid‑flex monolithics, and more compact interconnect geometries to address cryogenic signal‑connectivity scaling challenges in superconducting quantum systems.
Inspira Technologies (Nasdaq: IINN) received a fully paid $390,000 purchase order for an additive manufacturing electronics (AME) system from a premier APAC technological research university focused on quantum computing. The order also establishes a recurring revenue stream from consumables and fixed annual service fees. Inspira will deliver and deploy the AME system in the coming weeks and provide advanced application training for the university's research teams.
Inspira (Nasdaq: IINN) announced completion of commercial deployment of its Additively Manufactured Electronics (AME) system at a Tier‑1 U.S. defense customer on April 16, 2026. The delivery includes ongoing supply of proprietary consumables, creating a contractual basis for recurring revenue beyond the initial system sale.
The AME platform targets extreme miniaturization and complex integration needs across quantum computing, integrated photonics, and superconducting systems, and the company cites the deployment as evidence of commercial demand in advanced defense operations.
Inspira Technologies (NASDAQ: IINN) appointed Yoav Rozanovich as Chief Business Officer on April 14, 2026 to accelerate commercial execution after acquiring the Additive Manufacturing of Electronics (AME) business from Nano Dimension. Immediate priorities include integrating active AME revenue streams, driving AME sales conversion, and building quantum connectivity commercial pipelines.